CUTERA, INC., a leading provider of aesthetic and dermatological solutions, announces the launch of its Cutera Residency Program, a new program designed to expand access to AviClear®, the first FDA-cleared 1726 nm laser for the long-term treatment of mild, moderate, and severe acne, into dermatology training programs across North America.
This new program aims to support acne care innovation, research, and education by integrating AviClear into the clinical curriculum of leading academic institutions. By incorporating AviClear directly into residency programs, Cutera is equipping future dermatologists with the tools and technology they need to expand their armamentarium.
“Our goal is to empower the next generation of dermatologists through education and innovation,” said Taylor Harris, CEO of Cutera Inc. “By introducing AviClear into residency programs, we’re advancing clinical training while reinforcing our commitment to pioneering solutions that shape the future of dermatology and improve lives.”
The program establishes a 24-month partnership that includes technology integration and structured clinical training. Alongside education, it creates collaboration opportunities on publications, research, podium presentations, and exploration of new clinical indications. Looking ahead, the program also creates pathways to Cutera’s broader technology portfolio, ensuring participants gain exposure to a wide spectrum of innovations in dermatology and aesthetics.
“Residents will now have early access to cutting-edge technology like AviClear, giving them hands-on experience with the future of acne care,” said Ashish C. Bhatia, M.D., FAAD, Co-Director of Dermatologic, Laser and Cosmetic Surgery at Oak Dermatology. “At the same time, this partnership opens the door to exciting new research opportunities into sebaceous-based conditions such as sebaceous hyperplasia and hidradenitis suppurativa, expanding what’s possible in dermatologic care.”
Since the launch of AviClear, thousands of patient treatments have been performed world-wide, giving practitioners real-world evidence of its safety, effectiveness, and durability. Beyond acne, Cutera’s clinical research team is actively studying AviClear in a range of new indications tied to the sebaceous gland, including sebaceous hyperplasia, hidradenitis suppurativa, oily skin, and pore size, with additional exploratory research underway. These efforts highlight both the versatility and power of the 1726 nm wavelength and Cutera’s commitment to advancing innovation through clinical research.
Cutera is currently accepting applications from universities and programs interested in joining the Cutera Residency Program. Interested parties can apply and learn more by emailing residency@cutera.com.
For further information on Cutera and AviClear please visit www.cutera.com.
